Literature DB >> 9357863

Divergent regulation of 92-kDa gelatinase and TIMP-1 by HBECs in response to IL-1beta and TNF-alpha.

P M Yao1, B Maitre, C Delacourt, J M Buhler, A Harf, C Lafuma.   

Abstract

In this study, we addressed the question of whether human bronchial epithelial cells (HBECs) contribute to the regulation of 92-kDa gelatinase activity by secreting tissue inhibitor of metalloproteinase (TIMP)-1. We investigated expression of 92-kDa gelatinase and TIMP-1 in response to lipopolysaccharide (LPS) and to the proinflammatory cytokines interleukin (IL)-1beta and tumor necrosis factor (TNF)-alpha. Confluent HBECs from explants were cultured in plastic dishes coated with type I and III collagen. We demonstrated that TIMP-1 was expressed at both the protein and mRNA levels by primary cultures of HBECs. Gelatin zymography of HBEC-conditioned media showed that exposure of HBECs to LPS, IL-1beta, or TNF-alpha induced a twofold increase in the latent form of 92-kDa gelatinase production, as well as its activation. Also, quantitative reverse transcriptase (RT)-polymerase chain reaction (PCR) demonstrated a twofold increase in the 92-kDa mRNA level in response to both cytokines. In contrast, TIMP-1 production evaluated by immunoblotting was unchanged in the presence of LPS and IL-1beta and was clearly decreased in the presence of TNF-alpha. Quantitative RT-PCR demonstrated that TIMP-1 mRNA levels remained unchanged in response to LPS or IL-1beta but decreased by 70% in the presence of TNF-alpha. All of these results strongly suggest that the control mechanisms regulating the expression of 92-kDa gelatinase and TIMP-1 by HBECs in response to inflammatory stimuli are divergent and result in an imbalance between 92-kDa gelatinase and TIMP-1 in favor of the metalloproteinase. Such an imbalance may contribute significantly to acute airway inflammation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9357863     DOI: 10.1152/ajplung.1997.273.4.L866

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  5 in total

Review 1.  Matrix metalloproteinases in lung: multiple, multifarious, and multifaceted.

Authors:  Kendra J Greenlee; Zena Werb; Farrah Kheradmand
Journal:  Physiol Rev       Date:  2007-01       Impact factor: 37.312

2.  Tissue inhibitor of metalloproteinase-1 deficiency abrogates obliterative airway disease after heterotopic tracheal transplantation.

Authors:  Peter Chen; Alexander S Farivar; Michael S Mulligan; David K Madtes
Journal:  Am J Respir Cell Mol Biol       Date:  2005-12-30       Impact factor: 6.914

3.  Matrix Metalloproteinases on Severe COVID-19 Lung Disease Pathogenesis: Cooperative Actions of MMP-8/MMP-2 Axis on Immune Response through HLA-G Shedding and Oxidative Stress.

Authors:  Pedro V da Silva-Neto; Valéria B do Valle; Carlos A Fuzo; Talita M Fernandes; Diana M Toro; Thais F C Fraga-Silva; Patrícia A Basile; Jonatan C S de Carvalho; Vinícius E Pimentel; Malena M Pérez; Camilla N S Oliveira; Lilian C Rodrigues; Victor A F Bastos; Sandra O C Tella; Ronaldo B Martins; Augusto M Degiovani; Fátima M Ostini; Marley R Feitosa; Rogerio S Parra; Fernando C Vilar; Gilberto G Gaspar; José J R da Rocha; Omar Feres; Eurico Arruda; Sandra R Maruyama; Elisa M S Russo; Angelina L Viana; Isabel K F M Santos; Vânia L D Bonato; Cristina R B Cardoso; Jose E Tanus-Santos; Eduardo A Donadi; Lucia H Faccioli; Marcelo Dias-Baruffi; Ana P M Fernandes; Raquel F Gerlach; Carlos A Sorgi
Journal:  Biomolecules       Date:  2022-04-19

4.  The selected genetic polymorphisms of metalloproteinases MMP2, 7, 9 and MMP inhibitor TIMP2 in sarcoidosis.

Authors:  Wojciech J Piotrowski; Paweł Górski; Tadeusz Pietras; Wojciech Fendler; Janusz Szemraj
Journal:  Med Sci Monit       Date:  2011-10

5.  Influence of obesity on remodeling of lung tissue and organization of extracellular matrix after blunt thorax trauma.

Authors:  Pengfei Xu; Fabian Gärtner; Adrian Gihring; Congxing Liu; Timo Burster; Martin Wabitsch; Uwe Knippschild; Stephan Paschke
Journal:  Respir Res       Date:  2020-09-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.